T-cell function monitoring in stable renal transplant patients treated with sirolimus monotherapy

Molecular Diagnosis and Therapy

Volumn 11, Issue 4, 2007, Pages 247-256

  Brunet, Mercè ^a,b   Campistol, Josep Ma ^a   Diekmann, Fritz ^a   Guillen, David ^a   Millán, Olga ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; BIOLOGICAL MARKER; GAMMA INTERFERON; INTERLEUKIN 10; RAPAMYCIN; TRANSFORMING GROWTH FACTOR BETA;

ADULT; AGED; ARTICLE; CELL FUNCTION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG BLOOD LEVEL; FEMALE; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 34548392743     PISSN: 11771062     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03256246     Document Type: Article

References (27)

1. Pascual M, Theruvath T, Kawai T, et al. Strategies to improve long-term outcome after renal transplantation. N Eng J Med 2002; 346: 580-90
2. Flechner SM, Goldfarb D, Modlin Ch, et al. Kidney transplantation without calcineurin inhibitor drugs: a prospective randomized trial of SRL versus cyclosporine. Transplantation 2002; 74 (8): 1070-6
3. Mathew T, Kreis H, Friend P. Two-years incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies. Clin Transplant 2004; 18 (4): 446-9
4. Kauffman HM, Cherikh WS, Cheng Y, et al. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignances. Transplantation 2005; 80 (7): 883-9
5. Meier-Kriesche HU, Li S, Gruessner RW, et al. Immunosuppression: evolution in practice and trends, 1994-2004. Am J Transplant 2006; 6 (Pt 2): 1111-31
6. Millán O, Brunet M, Campistol JM, et al. Pharmacodynamic approach to immunosuppressive therapies using calcineurin inhibitors and mycophenolate mofetil. Clin Chem 2003; 49 (11): 1891-9
7. Brunet M, Martorell J, Oppenheimer F, et al. Pharmacokinetics and pharmacodynamics of mycophenolic acid in stable renal transplant recipients treated with low doses of mycophenolate mofetil. Transpl Int 2000; 13: S301-5
8. Millán O, Oppenheimer F, Brunet M, et al. Assessment of mycophenolic acid-induced immunosuppression, a new approach. Clin Chem 2000; 46 (9): 1376-83
9. Diekmann F, Gutierrez-Dalmau A, Torregrosa J, et al. Sirolimus monotherapy: feasible immunosuppression for long-term follow-up of kidney transplantation: a pilot experience. Transplantation 2005 Nov 15; 80 (9): 1344-8
10. Streit F, Armstrong V, Oellerich M. Rapid liquid chromatography-tandem mass spectrometry routine method for simultaneous determination of sirolimus, everolimus, tacrolimus and cyclosporine A in whole blood. Clin Chem 2002; 48 (6): 955-8
11. Millán O, Jiménez O, Fortuna V, et al. Role of FK778 or in combination with tacrolimus or mTOR inhibitors as an immunomodulator of immunofunctions: in vitro evaluation of T cell proliferation and the expression of lymphocyte surface antigens. Int J Immunophatol Pharmacol 2006; 19: 319-30
12. Barten MJ, Streit F, Boeger M, et al. Sinergistic effects of sirolimus with cyclosporine and tacrolimus: analysis of immunosuppression on lymphocyte proliferation and activation in rat whole blood. Transplantation 2004; 77 (8): 1154-62
13. Burkhart C, Heusser C, Morris RE, et al. Pharmacodynamics in the development of new immunosuppressant drugs. Ther Drug Monit 2004; 26 (6): 588-92
14. Klupp J, van Gelder T, Dambrin C, et al. Sustained suppression of peripheral blood immune functions by treatment with mycophenolate mofetil correlates with reduced severity of cardiac allograft rejection. J Heart Lung Transplant 2004; 23 (3): 334-51
15. Kowalski R, Post D, Schneider MC, et al. Immune cell function testing: an adjunct to therapeutic drug monitoring in transplant patient management. Clin Transplant 2003; 17: 77-88
16. Valero R, Sanchez-Velasco P, Rodrigo E, et al. Assesment about risk of infection in kidney transplant by measuring the concentration of atp from CD4 cells following stimulation by Cylex [poster abstract 1244]. World Transplant Congress; 2006 Jul 22-27; Boston. Am J Transplant 2006; 6 Suppl. 2: 486
17. Böhler T, Nolting J, Kamar N, et al. Validation of immunological biomarkers for the pharmacodynamic monitoring of immunosuppessive drugs in humans. Ther Drug Monit 2007; 29 (1): 77-86
18. Jorgensen PF, Wang JE, Almlöf M, et al. Sirolimus interferes with the innate response to bacterial products in human whole blood by attenuation of IL-10 production. Scand J Immunol 2001; 53: 184-91
19. Conti P, Kempuraj D, Kandere K, et al. IL-10, an inflammatory/inhibitory cytokine, but not always. Immunol Lett 2003; 86: 123-9
20. Corinti S, Albanesi A, la Sala A, et al. Regulatory activity of autocrine IL-10 on dendritic cell functions. J Immunol 2001; 166: 4312-8
21. Prakken BJ, Wendling U, van der Zee R, et al. Induction of IL-10 and inhibition of experimental arthritis are specific features of microbial heat shock proteins that are absent for other evolutionarily conserved immunodominant proteins. J Immunol 2001; 167: 4147-53
22. Fehérvari Z, Yamaguchi T, Sakaguchi S. The dichotomous role of IL-2: tolerance versus immunity. Trends Immunol 2006; 27 (3): 109-11
23. Boleslawski E, Conti F, Sanquer S, et al. Defective inhibition of peripheral CD8+T cell IL-2 production by anti-calcineurin drugs during acute liver allograft rejection. Transplantation 2004; Jun 27; 77 (12): 1815-20
24. Pankewycz O, Miao L, Isaacs R, et al. Increased renal tubular expression of transforming growth factor beta in human allografts correlates with cyclosporine toxicity. Kidney Int 1996; 50 (5): 1634-40
25. Yang W, Gao W, Zhang D, et al. Combination of rapamycin plus mutant TGF-β/Fc to induce immune tolerance [abstract 42]. World Transplant Congress; 2006 Jul 22-27; Boston. Am J Transplant 2006; 6 Suppl. 2: 80
26. Dodge IL, Demirci G, Strom TB, et al. Rapamycin induces transforming growth factor-β production by lymphocytes. Transplantation 2000; 70 (7): 1104-6
27. Chen YG, Liu F, Massagué J. Mechanism of TGF-β receptor inhibition by FKBP12. EMBO J 1997; 16: 3866-76